Aldeyra Therapeutics, Inc , a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases.
infoAldeyra Therapeutics is a small cap stock with a total market cap of 431.85M.
infoThey trade on the NASDAQ and had their IPO 9 years and 3 months ago.
infoAldeyra Therapeutics currently employs 15 people.
infoAs of Wednesday, Aug 23 2023, Aldeyra Therapeutics’s share price is $7.37.
News Relating to Aldeyra Therapeutics
Seeking Alpha
Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap
Monday Jul 10 2023 at 00:49
Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The company’s drug, reproxalap, is under FDA review for treating dry eye disease, with a decision expected in November 2023. Despite potential regulatory, market acceptance, financial, competition, and legal risks, Aldeyra Therapeutics is seen as a potential ‘Buy’ opportunity for long-term investors.
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
Wednesday Jun 28 2023 at 16:01
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 29, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑2191 in patients with retinitis pigmentosa. The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be acces.
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
Monday Jun 26 2023 at 16:01
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑629 in patients with chronic cough. The dial-in numbers are (888) 415‑4305 for domestic callers and (646) 960‑0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessible fro.
Zacks Investment Research
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study
Friday Jun 16 2023 at 11:35
Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.
Seeking Alpha
Aldeyra’s Stellar Allergic Conjunctivitis Results To Raise Reproxalap Monetization Value
Friday Jun 16 2023 at 10:55
Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease that provides immediate relief to patients. The trial results showed statistically significant improvements in allergic conjunctivitis and complements existing NDA for dry eye disease. With probable approval likely for both dry eye disease and allergic conjunctivitis, Reproxalap will be the subject of great pharma interest.
Schaeffers Research
Biotech Stock Surges on Eye Treatment Study
Thursday Jun 15 2023 at 11:31
Aldeyra Therapeutics Inc (NASDAQ:ALDX) is up 14.1% at $11.93 at last glance, after the biotech’s allergy treatment in the form of liquid eye drops, reproxalap, met its goal in a late-stage study.
Proactive Investors
Aldeyra Therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint
Thursday Jun 15 2023 at 10:49
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalmic solution for patients with allergic conjunctivitis has achieved statistical significance for the primary endpoint of ocular itching and all secondary endpoints in a Phase 3 clinical trial, sending the company’s stock soaring. “Consistent with the results of the Phase 3 INVIGORATE Trial and in conjunction with a number of successful Phase 2 and Phase 3 clinical trials in dry eye disease, achievement of the primary endpoint and all secondary endpoints in INVIGORATE-2 supports the potential of reproxalap as a treatment for inflammatory diseases of the ocular surface,” said Aldeyra CEO Dr. Todd Brady.
Reuters
Aldeyra Therapeutics eye treatment meets late-stage study main goal
Thursday Jun 15 2023 at 07:18
Aldeyra Therapeutics said on Thursday its experimental drug to treat an inflammatory eye disease met the main goal of reducing itching in a late-stage study.
Market Watch
Aldeyra Therapeutics’ stock jumps 11% premarket after announcing positive trial of treatment for allergic conjunctivitis
Thursday Jun 15 2023 at 07:18
Aldeyra Therapeutics Inc.’s stock ALDX, +0.63% jumped 11% premarket Thursday, after the biotech announced positive results from a late-stage trial of a treatment for allergic conjunctivitis. The Lexington, Mass.
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
Wednesday Jun 14 2023 at 16:01
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 15, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 INVIGORATE‑2 Trial of reproxalap in allergic conjunctivitis. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 349573. A live audio webcast of the conference call also will be accessible.
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Friday Jun 02 2023 at 07:00
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Dr. Brady’s conversation with Kelly Shi, Ph.D., Senior Research Analyst at Jefferies, is scheduled to begin at 9:30 a.m. E.
Seeking Alpha
Buy Aldeyra Therapeutics For Consecutive Runups
Saturday May 06 2023 at 01:23
They headlined 3 top-line results coming in Q2 2023. An all-important PDUFA Date is on tap in June.
Seeking Alpha
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript
Thursday Mar 09 2023 at 10:45
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Bruce Greenberg – Interim Chief Financial Officer Todd Brady – President and Chief Executive Officer Conference Call Participants Marc Goodman – SVB Securities Yigal Nochomovitz – Citigroup Justin Kim – Oppenheimer & Co. Catherine Novack – Jones Research Yale Jen – Laidlaw & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Seeking Alpha
Aldeyra Therapeutics: NDA Submission For Large Multi-Billion Dollar Market
Sunday Dec 11 2022 at 07:17
New Drug Application of Reproxalap for the treatment of patients with dry eye disease submitted on November 29, 2022; Potential FDA approval possible in late 2023. Results from the phase 3 INVIGORATE-2 study using reproxalap for the treatment of patients with allergic conjunctivitis are expected in 2023.
Seeking Alpha
Aldeyra Therapeutics, Inc. (ALDX) Q3 2022 Earnings Call Transcript
Thursday Nov 10 2022 at 13:40
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Bruce Greenberg – Interim Chief Financial Officer Todd Brady – President and Chief Executive Officer Conference Call Participants Marc Goodman – SVB Securities Justin Kim – Oppenheimer Yale Jen – Laidlaw & Co. Catherine Novack – Jones Research Operator Ladies and gentlemen, thank you for standing by and welcome to the Aldeyra Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Wednesday Oct 05 2022 at 16:05
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy. The dial-in numbers
Seeking Alpha
Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA
Monday Sep 19 2022 at 08:28
Shares have bucked weakness in the biotech sector and risen 60% year to date. Dry eye disease is a lucrative indication for reproxalap (albeit with generic competition) and differentiation is apparent via fast onset of action and statistical significance across multiple signs.
Seeking Alpha
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results – Earnings Call Transcript
Friday Aug 05 2022 at 14:01
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Bruce Greenberg – Interim Chief Financial Officer Todd Brady – President & Chief Executive Officer Conference Call Participants Catherine Novack – Jones Research Yigal Nochomovitz – Citigroup Kelly Shi – Jefferies Tom Shrader – BTIG Justin Kim – Oppenheimer & Co. Yale Jen – Laidlaw & Company Operator Ladies and gentlemen, thank you for standing by and welcome to the Aldeyra Therapeutics Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Seeking Alpha
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Thursday Aug 04 2022 at 02:25
Reproxalap seems poised for FDA approval for dry eye disease. Therapy has clear practical advantages over Restasis and Xiidra.
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
Friday Jul 29 2022 at 08:00
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter ended June 30, 2022 and discuss recent corporate highlights. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 908644. A live audio webcast of the conference call also will be accessible from the “Investors & Media” sectio
Zacks Investment Research
Aldeyra’s (ALDX) Dry Eye Disease Chamber Study Meets Goals
Wednesday Jul 13 2022 at 13:05
Aldeyra’s (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Benzinga
Aldeyra’s Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
Tuesday Jul 12 2022 at 09:03
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disease. Relative to the vehicle, a statistically significant reduction in ocular.
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
Monday Jul 11 2022 at 16:05
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report top-line results from the crossover clinical trial of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 853619. A live audio webcast o
Benzinga
Why Aldeyra Therapeutics’ Shares Are Soaring Today?
Wednesday Jun 08 2022 at 09:47
Aldeyra Therapeutics Inc’s (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and ≥10 mm Schirmer.
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Tuesday Jun 07 2022 at 16:05
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call also will be accessible from th
Business Wire
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
Monday May 23 2022 at 16:05
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. Dr. Brady’s conversation with Matthew Caufield, Vice President, Equity Research for H.C. Wainwright, will be available o
Benzinga
Aldeyra’s Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness
Wednesday May 18 2022 at 15:29
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported a post-hoc analysis from the completed Phase 3 TRANQUILITY dry eye chamber trial of reproxalap for dry eye disease. Using computer-automated grading of digital photography from the trial demonstrated statistical significance in favor.
Seeking Alpha
Aldeyra Therapeutics Inc. (ALDX) CEO Dr. Todd Brady on Q1 2022 Results – Earnings Call Transcript
Thursday May 05 2022 at 15:49
Aldeyra Therapeutics Inc. (NASDAQ:ALDX ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Joshua Reed – Chief Financial Officer Dr. Todd Brady – Chief Executive Officer Bruce Greenberg – Incoming Interim CFO Conference Call Participants Justin Kim – Oppenheimer Marc Goodman – SVB Leerink Yigal Nochomovitz – Citi Kelly Shi – Jefferies Sung Hong – BTIG Matthew Cross – Alliance Global Partners Catherine Novack – Jones Trading Elaine Kim – Berenberg Yale Jen – Laidlaw Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Seeking Alpha
Aldeyra Therapeutics’ (ALDX) CEO Todd Brady on Q4 2021 Results – Earnings Call Transcript
Thursday Mar 17 2022 at 13:47
Aldeyra Therapeutics’ (ALDX) CEO Todd Brady on Q4 2021 Results – Earnings Call Transcript
Seeking Alpha
Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Thursday Feb 17 2022 at 15:30
Aldeyra Therapeutics is currently undervalued with near-term catalysts, in my view.
Aldeyra Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Aldeyra Therapeutics’s Altman Z-score is 6.54 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Aldeyra Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Aldeyra Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Aldeyra Therapeutics’s Income Quality of 0.63 is in line with its Industry Group of 0.69 (-8.7% lower)
Aldeyra Therapeutics’s Income Quality of 0.63 is lower than its Major Industry Group of 0.71 (-11.3% lower)
Aldeyra Therapeutics’s Income Quality of 0.63 is lower than its Sector of 0.75 (-16.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Aldeyra Therapeutics’s Current Ratio of 9.96 is greater than its Industry Group of 4.76 (109.2% greater)
Aldeyra Therapeutics’s Current Ratio of 9.96 is greater than its Major Industry Group of 4.32 (130.6% greater)
Aldeyra Therapeutics’s Current Ratio of 9.96 is greater than its Sector of 2.6 (283.1% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-8.58 & -1.27)
Cannot compare a negative PE Ratio (-8.58 & -1.1)
Cannot compare a negative PE Ratio (-8.58 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Aldeyra Therapeutics’s PB Ratio of 3.32 is greater than its Industry Group of 1.34 (147.8% greater)
Aldeyra Therapeutics’s PB Ratio of 3.32 is greater than its Major Industry Group of 1.4 (137.1% greater)
Aldeyra Therapeutics’s PB Ratio of 3.32 is greater than its Sector of 1.62 (104.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aldeyra Therapeutics’s ROE of -0.39 is greater than its Industry Group of -0.44 (11.4% greater)
Aldeyra Therapeutics’s ROE of -0.39 is in line with its Major Industry Group of -0.38 (-2.6% lower)
Aldeyra Therapeutics’s ROE of -0.39 is lower than its Sector of -0.03 (-1200.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aldeyra Therapeutics’s ROCE of -0.4 is in line with its Industry Group of -0.42 (4.8% greater)
Aldeyra Therapeutics’s ROCE of -0.4 is in line with its Major Industry Group of -0.37 (-8.1% lower)
Aldeyra Therapeutics’s ROCE of -0.4 is lower than its Sector of -0.04 (-900.0% lower)
Derived from SEC.GOV filing dataopen_in_new